Press Releases

December 10, 2015 » Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting

November 16, 2015 » NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD

May 4, 2015 » NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

January 6, 2015 » FDA Grants NeuroSigma Humanitarian Use Device (HUD) Designation

January 5, 2015 » UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System

November 19, 2014 » NeuroSigma Congratulates Brazilian Medical Team for Their Top-Line Results in Phase II Clinical Trial of eTNS for Treatment of Depression

November 17, 2014 » NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression

November 3, 2014 » NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)

October 21, 2014 » NeuroSigma Receives Notice of Allowance of U.S. Patent Application

October 15, 2014 » NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

August 26, 2014 » NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

August 25, 2014 » U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

July 22, 2014 » Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

July 9, 2014 » NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

July 8, 2014 » Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

June 3, 2014 » Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

April 1, 2014 » NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

March 28, 2014 » NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

February 25, 2014 » David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

February 11, 2014 » Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

January 27, 2014 » Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer

January 21, 2014 » External Trigeminal Nerve Stimulation (eTNS) Presentations at the American Epilepsy Society Meeting

December 5, 2013 » NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders

July 29, 2013 » NeuroSigma Announces FDA Approval to Commence Phase III Trial

June 21, 2013 » NeuroSigma Announces Debut of Its Monarch eTNS System in Canada

June 6, 2013 » NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression

May 20, 2013 » Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)

May 2, 2013 » NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder

April 18, 2013 » Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD

March 25, 2013 » External Trigeminal Nerve Stimulation (eTNS) For Refractory Status Epilepticus

February 11th, 2013 » NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London

February 4th, 2013 » NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy

January 30th, 2013 » NeuroSigma Announces Publication of Randomized Controlled Trial of eTNS for Treatment of Drug Resistant Epilepsy in the Leading Journal, Neurology®

January 22nd, 2013 » NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders

September 25th, 2012 » NeuroSigma's Monarch eTNS System to be Unveiled in London

September 5th, 2012 » NeuroSigma Receives CE Certification

July 2nd, 2012 » NeuroSigma Receives Global Quality Control Certification

May 30th, 2012 » Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™

May 16th, 2012 » NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio

May 8th, 2012 » Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™

April 9th, 2012 » NeuroSigma Awarded NIH Grant for Further Development of Its Thin-Film Nitinol Covered Neurovascular Stent

April 2nd, 2012 » UCLA Neurologist and Innovator of Trigeminal Nerve Stimulation Joins NeuroSigma

November 29th, 2011 » NeuroSigma to Exhibit at the 2011 American Epilepsy Society Annual Meeting and Introduce External Trigeminal Nerve Stimulation - the USB Port to the Brain™

October 24th, 2011 » NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD

September 6th, 2011 » NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy

August 4th, 2011 » NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial

July 18th, 2011 » NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLA's Thin-Film Nitonol (TFN) Stent Technology for Endovascular Applications

July 5th, 2011 » Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™

April 28th, 2011 » Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™)

April 25th, 2011 » NeuroSigma Provides Update on Trigeminal Nerve Stimulation (TNS) - the USB Port to the Brain

April 4th, 2011 » NeuroSigma, Inc. Retains CCG Investor Relations

December 3rd, 2010 » Report Favorable Results of Pilot Feasibility Trial for Trigeminal Nerve Stimulation for Epilepsy

September 2nd, 2010 » Non-invasive therapy signficiantly improves depression, UCLA researchers say


Back to Top